Skip to content

Global Cancer/Tumor Profiling Market to Generate $31.67

New York, Aug. 01, 2022 (GLOBE NEWSWIRE) — According to the report published by Next Move Strategy Consulting, the global cancer/tumor profiling market generated USD 11.10 billion in 2021, and is projected to reach USD 31.67 billion by 2030, witnessing a CAGR of 11.8% from 2022 to 2030. The report provides an extensive analysis of changing market dynamics such as driving factors and opportunities, top segments & their sub-segments, and leading market players.

Offering an entire analysis, data, and statistics in nearly 600 pages and representing crucial information in 760 tables and nearly 400 figures, the report aims to offer a thorough picture of the market to industry giants, investors, new entrants, and stakeholders for devising new strategies and raising their cancer/tumor profiling market share. It also offers the Covid-19 impact on the global market.

Request a free sample:

Report Coverage Details
Forecast Period 2022–2030
Base Year 2021
Market Size in 2021 $11.10 Billion
Market Size in 2030 $31.67 Billion
CAGR 11.8%
No. of Pages 592
tables 760
figures 387
segments covered Technique, Technology, Application, and Geography.
drivers Increase in new cancer cases
Surge in adoption of precision medicine options
Opportunities Unmet needs and economic development in the developing countries
Surge in new product approvals

The report provides detailed analysis of driving factors, restraints, and opportunities of the global cancer/tumor profiling market. It is helpful for market players and investors in devising strategies based on factors that would give huge returns on their investments and raise market share. Increase in new cancer cases with aging population & lifestyle changes and surge in adoption of precision medicine options drive the growth of the global cancer/tumor profiling market. Moreover, it arises in research and development activities supplement the market growth. However, high cost of cancer profiling tests and poor reimbursement policies restrain the market growth.

Outlining the opportunities that play a crucial role in increasing the global cancer/tumor profiling market size in the next few years, the Lead Analyst for the Life Sciences & Healthcare category at Next Move Strategy Consulting, stated, “A lot of unmet needs and economic development in the developing countries presents new opportunities in the coming years. In addition, arises in new product approvals create new avenues for the growth for market players.”

Buy this report directly from here:

The report provides a detailed analysis of top segments and their sub-segments of the global cancer/tumor profiling market. With the help of tables and figures, the research provides extensive analysis of segments such as technique, technology, application, and geography. Based on technique, the research divides the market into genomics, metabolomics, proteomics, and epigenomics. Based on technology, the research classifies the market into immunoassay, insitu hybridization, NGS, PCR, mass spectrometry, microarray, and others. Furthermore, the insitu hybridization segment is sub-classified into FISH and CISH.

Based on application, the research bifurcates the market into research applications and clinical applications. Moreover, the research applications segment is further divided into biomarker discovery and personalized cancer medicine. The clinical application segment is further classified into prognostics, oncological diagnostics, monitoring and treatment, and screening.

Need a customized report, get in touch with us here:

Based on geography, the research sub-categorized the market into North America, Europe, Asia-Pacific, and RoW. Based on report, North America accounted for the highest share in 2021, and is estimated to maintain its dominance during the forecast period. This is due to rise in new product launches in countries such the US and Canada, increase in prevalence of cancer, and advancements in technologies. However, Asia-Pacific is projected to register the fastest growth rate during the forecast period, owing to enhanced healthcare infrastructure and economic developments in emerging countries in the region.

The report offers a detailed analysis of each region and their respective countries based on the aforementioned segments and sub-segments. This analysis will help in gaining detailed scenario of the global cancer/tumor profiling industry.

If you have any queries, you can inquire before purchasing:

The report highlights the competitive landscape of the global cancer/tumor profiling market by analyzing leading players based on various parameters such as business performance, key strategies and developments, and others. The report analyzes leading players including Lucence Health, Inc., Caris Life Sciences, F. Hoffmann-La Roche, Ltd., ACT Genomics Co., Ltd., Strand Life Sciences, Thermo Fisher Scientific, Inc., Illumina, Inc., IMB Dx, Inc., QIAGEN, Guardant Health, HTG Molecular Diagnostics, Inc., Ribomed Biotechnologies, Inc., NeoGenomics Laboratories, NanoString, and Exact Sciences Corporation (Genomic Health, Inc.).

Buy a full report here:

Also, Browse Related Reports:

Cancer Drug Market by Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), and Hormonal Therapy), by Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other) – Global Opportunity Analysis and Industry Forecast, 2020–2030

Cancer Vaccines Market by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvent Cancer Vaccines, Viral Vector and DNA Cancer Vaccines), Type (Preventive Vaccine, Therapeutic Vaccine), Indication (Prostate Cancer, Cervical Cancer, Others), End User (Adult Vaccines, Pediatric Vaccine) – Global Opportunity Analysis and Industry Forecast, 2019–2030

Breast Cancer Therapeutics Market by Cancer Type (Hormone Receptor and HER2+), by Therapy (Radiation Therapy, Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy, and Others), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others), and by End -Users (Hospitals, Cancer Research Organizations, Specialty Clinics, Ambulatory Centers, and Others) – Global Opportunity Analysis and Industry Forecast 2022-2030

About Us:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analyzed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to make critical business decisions that enable them to move beyond time and have a competitive edge in the industry.

We have been serving over 1,000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.



Leave a Reply

Your email address will not be published.